Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Director · PRESIDENT AND CEO | August 24, 2023 | February 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Verrica Pharmaceuticals Inc.
Report date August 24, 2023 · Filed February 06, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 278,789 |
Reported balance
After 2023-08-24 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2023-08-24 · Grant · Acquired 150,000 · Balance 278,789 F1: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale. F2: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale.
F2: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2024 Filed Aug 28, 2024 20:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 9,021 | $2.46 | $22,191.66 |
DisclosureSEC source: 0001415889-24-022423 · form4-08282024_040801.xml · nonDerivative · entry 2 White Ted · CIK 0001741964 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,967 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.53 inclusive. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 24,979 | $2.66 | $66,444.14 |
DisclosureSEC source: 0001415889-24-022423 · form4-08282024_040801.xml · nonDerivative · entry 1 White Ted · CIK 0001741964 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,988 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| July 23, 2024 Filed Jul 23, 2024 22:13 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 154 | $6.98 | $1,074.92 |
DisclosureSEC source: 0001415889-24-019976 · form4-07232024_100700.xml · nonDerivative · entry 2 White Ted · CIK 0001741964 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,967 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 22:13 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 32,469 | $7.06 | $229,231.14 |
DisclosureSEC source: 0001415889-24-019976 · form4-07232024_100700.xml · nonDerivative · entry 1 White Ted · CIK 0001741964 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,121 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:31 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001415889-24-008538 · form4-03192024_040342.xml · derivative · entry 2 White Ted · CIK 0001741964 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2034-03-15 F2 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 15, 2025 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:31 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 112,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008538 · form4-03192024_040342.xml · nonDerivative · entry 1 White Ted · CIK 0001741964 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,590 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in equal annual installments on March 15, 2025, March 15, 2026, March 15, 2027 and March 15, 2028 subject to the Reporting Person's continuous service through each applicable date. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:33 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 11,558 | $2.97 | $34,327.26 |
DisclosureSEC source: 0001209191-23-055528 · doc4.xml · nonDerivative · entry 2 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,090 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $3.00 inclusive. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:33 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 22,141 | $2.93 | $64,873.13 |
DisclosureSEC source: 0001209191-23-055528 · doc4.xml · nonDerivative · entry 1 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,648 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| August 24, 2023 Filed Aug 28, 2023 20:39 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-047523 · doc4.xml · nonDerivative · entry 1 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,789 F1 · shares: Represents vesting of shares of common stock underlying performance stock units resulting from the achievement of certain non-financial milestones. These shares have not been delivered. Read SEC document |
| August 24, 2023 Filed Feb 6, 2025 21:15 UTC Amendment | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003231 · form4a-02062025_040204.xml · nonDerivative · entry 1 White Ted · CIK 0001741964 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,789 F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale. F2 · shares: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction. F2 · balance_after: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 20:18 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 50,677 | $4.83 | $244,769.91 |
DisclosureSEC source: 0001209191-23-043297 · doc4.xml · nonDerivative · entry 2 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,789 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on July 21, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 20:18 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043297 · doc4.xml · nonDerivative · entry 1 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,466 F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in 2019 and 2020. The RSUs vested 50% upon receipt of regulatory approval of the Issuer's new drug application for VP-102 for the treatment of molluscum, and the remaining 50% shall vest on July 21, 2024, subject to the Reporting Person's continuous service through each applicable date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:29 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 240,000 | $0.00 Strike: $7.58 | $0.00 |
DisclosureSEC source: 0001209191-23-015511 · doc4.xml · derivative · entry 1 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2033-02-28 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 1, 2024 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| July 05, 2022 Filed Jul 5, 2022 20:13 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 23,809 | $2.10 | $49,998.90 |
DisclosureSEC source: 0001209191-22-040608 · doc4.xml · nonDerivative · entry 1 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,466 Read SEC document |
| July 05, 2022 Filed Feb 21, 2023 21:08 UTC Amendment | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 7,500 | $2.10 | $15,750.00 |
DisclosureSEC source: 0001209191-23-011127 · doc4a.xml · nonDerivative · entry 1 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,466 F1 · shares: The original Form 4 inadvertently listed the incorrect number of shares purchased by the Reporting Person. This represents the correct number of shares. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 21:30 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013191 · doc4.xml · derivative · entry 1 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-02-23 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on February 24, 2023 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 12:44 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 4,000 | $9.95 | $39,800.00 |
DisclosureSEC source: 0001209191-21-038482 · doc4.xml · nonDerivative · entry 1 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,966 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.80 to $10.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:06 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $14.32 | $0.00 |
DisclosureSEC source: 0001209191-21-017004 · doc4.xml · derivative · entry 1 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2031-02-28 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 1, 2022 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 20:37 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 10,661 | $6.28 | $66,951.08 |
DisclosureSEC source: 0001209191-20-046961 · doc4.xml · nonDerivative · entry 1 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,966 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $6.2493 to $6.4086, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:46 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $11.81 | $0.00 |
DisclosureSEC source: 0001209191-20-014686 · doc4.xml · derivative · entry 1 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-02-26 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on February 27, 2021 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:29 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001209191-19-015808 · doc4.xml · derivative · entry 1 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-02-27 F1 · derivative.exercise_date: 25% of shares subject to the option shall vest on February 28, 2020 (the "Initial Vesting Date"), and 1/48th of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Initial Vesting Date, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 20:32 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 300 | $16.36 | $4,908.00 |
DisclosureSEC source: 0001209191-18-047752 · doc4.xml · nonDerivative · entry 1 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,305 Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 21:02 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 600 | $16.40 | $9,840.00 |
DisclosureSEC source: 0001209191-18-047102 · doc4.xml · nonDerivative · entry 2 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,005 Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 21:02 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 1,905 | $15.47 | $29,470.35 |
DisclosureSEC source: 0001209191-18-047102 · doc4.xml · nonDerivative · entry 1 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,405 F1 · price: This transaction was executed in multiple trades at prices ranging from $15.30 to $15.57, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| June 19, 2018 Filed Aug 15, 2018 20:49 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 4,500 | $15.00 | $67,500.00 |
DisclosureSEC source: 0001209191-18-046828 · doc4.xml · nonDerivative · entry 1 White Ted · CIK 0001741964 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.